Literature DB >> 11250797

Adenoma of the posterior urethra: 131 case report.

Z G Mi1, X F Yang, X Z Liang, H Y Liu, S Y Liu, H Zhang, D W Wang, C Liu.   

Abstract

AIM: A case-report on adenoma of the posterior urethra.
METHODS: In 131 cases of adenoma of the posterior urethra, aged 17-79 (mean: 36.4) years, a detailed medical history was taken and urinalysis, urethroscopy, and prostatic specific antigen (PSA) immunohistochemical staining were performed. They were then treated with transurethral resection (TUR) or transurethral electric coagulation (TUEC).
RESULTS: Hemospermia occurred in 51% of the cases, hematuria in 38%, blood overflow from the urethral orifice in 6%, and dysuria in 5%. The position of the tumor was at or around the verumontanum. The appearance of the tumor was similar to those of a papilla, a villus, a dactyl or polyp, or simply an engorgement. The tumor contained glandular alveoli and adeno-epithelial cells. PSA immunohistochemistry was positive in the cytoplasm and nucleus of the adeno-epithelial cell. One hundred and tweenty-nine cases were cured after TUR or TUEC, while 2 patients recurred and were operated again.
CONCLUSION: Adenoma of the posterior urethra is a common cause of hemospermia and hematuria in young men. Urethroscopic examination and biopsy are the principal diagnostic measures. TUR or TUEC are believed to be the treatment of choice with a short-term recurrence rate of around 1. 5%.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250797

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  2 in total

Review 1.  MR findings of prostatic urethral polyp in an adult.

Authors:  Hong Li; Kazuro Sugimura; Michiko Boku; Yasushi Kaji; Mayumi Tachibana; Sadao Kamidono
Journal:  Eur Radiol       Date:  2002-10-24       Impact factor: 5.315

2.  Genito-urinary polyps: summary of the 10-year experiences of a single institute.

Authors:  Abhay Kumar; Suren K Das; Sameer Trivedi; Udai S Dwivedi; Pratap B Singh
Journal:  Int Urol Nephrol       Date:  2008-05-06       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.